Premium
Total and regional bone mass and biochemical markers of bone remodeling in metastatic prostate cancer
Author(s) -
Revilla M.,
Arribas I.,
SanchezChapado M.,
Villa L.F.,
Bethencourt F.,
Rico H.
Publication year - 1998
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(19980601)35:4<243::aid-pros2>3.0.co;2-h
Subject(s) - prostate cancer , medicine , bone remodeling , prostate , bone mass , cancer , pathology , oncology , bone metastasis , osteoporosis
BACKGROUND The osteolytic activity of metastases of prostate cancer was evaluted in relation to total body bone mineral content (TBBMC) and regional bone mineral content (RBMC). METHODS Bone mass was determined by dual‐energy X‐ray absorptiometry (DXA). Tartrate‐resistant acid phosphatase (TRAP) was measured as a biochemical marker of bone resorption. RESULTS In 32 patients (mean age 72 ± 4 years) compared with 32 controls (mean age 73 ± 5 years), there were significant differences in TRAP ( P < 0.0001), TBBMC ( P < 0.0001), and RBMC in the pelvis ( P < 0.0001), legs ( P = 0.0001), and trunk ( P <0.05), but not in the arms and head ( P = ns). In the overall group of subjects, the correlation between TBBMC and TRAP was r = ‐0.68, P < 0.0001. The correlations remained significant in the patient and control groups separately. CONCLUSIONS The loss of bone mass observed in patients with metastatic prostate cancer was caused mainly by the predominance of bone resorption in the osteoblastic metastases. Prostate 35:243–247, 1998. © 1998 Wiley‐Liss, Inc.